Helix BioPharma Corp. take stock of the company

Enter Wall Street with Street Insider Premium. Claim your 1-week free trial here.

RICHMOND HILL, ON / ACCESSWIRE / December 31, 2021 / Helix BioPharma Corp. (TSX: HBP) ​​(“Helix” or the “Company”), an immuno-oncology company that develops innovative drug candidates for the prevention and treatment of cancer, is pleased to provide an update on initiatives undertaken by the Company in 2021.

Despite the challenges posed by the COVID-19 pandemic, 2021 has been a productive year for the Company. During the second half of 2021, the Company initiated efforts to validate Helix and its core clinical program with external stakeholders to provide an outside perspective on the strategy and future of the company, including, but without limitation, the following actions:

  • In May 2021, Helix retained the consulting services of Dr. Christof Boehler, PhD, a seasoned biotechnology scientist and entrepreneur to evaluate Helix and its assets. The result of this engagement has been a positive outlook on the potentials of L-DOS47, which has been shown to be safe in approximately 100 patients to date in the Company’s Phase 1 clinical trials. Given the limitations of the current standard of care for meeting the high unmet medical needs in oncology, the Company believes that the unique characteristics of L-DOS47 position Helix as one of the leaders in the development of new avenues such as microenvironments. (change in tumor pH), with the aim of improving the results of the treatment of various malignancies with the use of L-DOS47 in combination with immunotherapy and / or chemotherapy.
  • In addition to Dr. Boehler’s assessment, Helix also retained the services of a very experienced oncology consulting firm, Cello Healthcare (“Cello“), in August 2021. A major aspect of this engagement included interviews with some key opinion leaders in the field to obtain their comments and recommendations on the Company’s L-DOS47 technology platform. The outcome of these interviews conducted by Cello both validated the clinical work performed by Helix to date, and also helped the Company identify additional opportunities to strengthen and reduce the risks of the Company’s clinical program, including optimal patient selection for trials (stratification) based on objective biomarkers, among other criteria. that these activities will facilitate strategic dialogue with potential leaders in the cancer treatment market, and that the additional preclinical data obtained will further improve the design of the clinical program of the society.
  • Finally, in September 2021, Helix retained the advisory services of Dr Atul Deshpande, PhD, MBA, another seasoned biotechnology executive who helped his former employer, an immuno-oncology company, raise significant funds from venture capital fund and to design a strategy and execution plan with a view to the Company’s IPO and significant concomitant financing. In his role as a consultant, Dr Deshpande has been tasked with implementing a business strategy and updated clinical plans to help the Company achieve its goals.

Dr Slawomir Majewski, CEO and Interim Director, said “We hope that this type of external validation combined with internal expertise and experience will allow Helix to remain focused on advancing towards the development of unique therapies in the field of immuno-oncology for the treatment of cancer. We will continue to partner with these seasoned advisors and subject matter experts to increase the value of our platform and assets.

“Our clinical program remains our top priority to ensure we deliver a substantial data set that would ultimately benefit patients and stakeholders. We are awaiting final trial reports from Phase I and II studies in lung cancer in 2022. The other clinical trial in pancreatic cancer is continuing and we remain committed to this study. Additionally, in May 2021, we announced an agreement with Lind Global Macro Fund, LP, and subsequently closed a first tranche of funding for gross proceeds of $ 3,500,000. We are also working diligently to identify potential candidates for the position of permanent CEO of the Company, ”continued Dr. Majewski.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary DOS47 technology platform. Helix is ​​listed on the Toronto Stock Exchange under the symbol “HBP”.

For more information please contact:
Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9
Phone. : 905-841-2300 ext 233
Frank Michalargias, Chief Financial Officer
[email protected]

Forward-looking statements and risks and uncertainties

This press release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts, but rather include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations regarding the business, operations, the future research and development of the Company, including the business of the Company. regarding DOS47, and statements regarding the Company’s belief that it is positioned as a leader in the treatment of new cancer treatment pathways, the belief that the Company’s recent actions will provide opportunities to reduce the risks of the clinical program of the Company and enhance the value of the Company’s platform and assets, expectations regarding dialogue with market leaders, expectations regarding improved clinical program design, expectations regarding clinical trial schedule and the results of these tests, and statements concerning the identification and appointment of a permanent general manager. Forward-looking statements may be further identified by the use of forward-looking terminology such as “current”, “estimates”, “expect”, or the negative thereof or any other variation thereof or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could” or “should” occur or be achieved, or comparable terminology referring to events or future results.

Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based on a number of estimates and assumptions which are also uncertain. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve risks and uncertainties, and one should not place undue reliance on such statements. Forward-looking statements, including the financial outlook, are intended to provide information about management’s current plans and expectations regarding future operations, including, without limitation, future funding requirements, and may not be suitable for other purposes. Certain important factors, estimates or assumptions have been applied in making forward-looking statements in this press release, including, but not limited to, the ability of the Company to file annual documents within the time frame described herein.

The actual results of the Company could differ materially from those anticipated in the forward-looking statements contained in this press release due to numerous known and unknown risks and uncertainties, including, without limitation, the risk that the Company may not be able to file annual documents. within the proposed timeframe; the risk that the Company’s assumptions may prove to be incorrect; the risk that additional funding may not be obtained in a timely manner, if at all, and that clinical trials may not start or end on time or on budget or fail; third-party suppliers of necessary services or pharmaceuticals and other materials may not function or be unwilling or unable to supply the Company, which could delay or cancel the Company’s research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to obtain the necessary strategic support from its partners; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties mentioned elsewhere in this press release, each of which could cause actual results to differ materially from current results or anticipated future results of the Company. Some of these risks and uncertainties, and others affecting the Company, are described in more detail in the Company’s annual management report for the year ended July 31, 2021 under the heading “Risks and uncertainties” and the annual information form. Helix, in particular under the headings “Forward-Looking Statements” and “Risk Factors” and other reports filed under the Company’s profile on SEDAR at www.sedar.com sometimes. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix management as of the date of this new press release, and the Company assumes no obligation to update any forward-looking statements or information if such beliefs , assumptions, opinions or expectations, or other circumstances change, except as required by law.

THE SOURCE: Helix BioPharma Corp.

See the source version on accesswire.com:

Comments are closed.